Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome by Ruiz-Moreno, JM et al.
Intravitreal anti-VEGF therapy for choroidal
neovascularisation secondary to pathological
myopia: 4-year outcome













4Ophthalmology Unit, Pío del
Río Hortega University
Hospital, Valladolid, Spain







Hospital of Coimbra, Coimbra,
Portugal
Correspondence to
Professor Jose M Ruiz-Moreno,
Departamento de Ciencias
Médicas, Facultad de
Medicina, Avda de Almansa,
14., Albacete 02006, Spain;
josemaria.ruiz@uclm.es
Received 8 December 2012
Revised 6 August 2013
Accepted 27 August 2013
Published Online First
11 September 2013
To cite: Ruiz-Moreno JM,




Objective To report the visual outcome after 4-year
follow-up in a series of highly myopic eyes with
choroidal neovascularisation (CNV) treated with
antivascular endothelial growth factor (anti-VEGF) drugs.
Methods A retrospective, non-randomised, multicentre,
consecutive, interventional case series study was
performed. 92 highly myopic eyes with subfoveal CNV
were treated with intravitreal injection (IVI) of anti-VEGF.
The initial protocol (1 vs 3 injections) was dictated by
surgeons’ preferences and followed by an as-needed
monthly regime. Best-corrected visual acuity (BCVA) was
evaluated at baseline and then monthly. The primary aim
was to analyse BCVA changes. The effect of age,
spherical equivalent (SE) and treating drug were
evaluated as secondary objectives.
Results The mean age of the patients was 57 years
(SD 14, range 30–93). The mean number of letters read
was 46.1 (SD 16.8, range 5–70) at baseline, 55.5 (SD
18.6, range 10–85) at 12 months, 50.1 (SD 20.1, range
5–82) at 24 months, 54.2 (SD 21.9, range 2–85) at
36 months and 53.1 (SD 22.5, range 1–83) at
48 months (p=0.000, initial vs 12, 24 and 36 months;
p=0.01 initial vs 48 months; Student t test for paired
data). The mean total number of IVI was 4.9 (SD 5.4,
range 1–29). SE and treating drug had no inﬂuence on
the ﬁnal visual outcome and number of injections
required.
Conclusions Intravitreal bevacizumab and ranibizumab
are effective therapies and show similar clinical effects in
highly myopic CNV. Visual acuity gain is maintained at
4-year follow-up.
INTRODUCTION
The standard care for myopic choroidal neovascu-
larisation (CNV) is photodynamic therapy with ver-
teporﬁn (PDT).1 Antivascular endothelial growth
factor (anti-VEGF) drugs such as ranibizumab2 and
bevacizumab3–6 have been used off-label to treat
CNV secondary to high myopia with good results.
Several studies have reported on the outcome of
intravitreal bevacizumab (IVB) in the short term4 6
at 13 5 and 2 years follow-up,7 8 and intravitreal
ranibizumab (IVR) at 2 years.9 10 More recently,
Hefner and Peiretti reported on their results with
IVR and IVB at 3 and 4 years, respectively.11 12
The initial therapeutic protocol has consisted of
3-monthly consecutive injections5 or one single
injection.3 The results of three versus one loading
dose have been published.13 The outcomes of PDT
and IVB to treat myopic CNV have been compared,
suggesting that bevacizumab is more effective than
PDT.14
The purpose of this study is to evaluate the
visual acuity changes during a 4-year follow-up
period in a large series of highly myopic eyes with
CNV treated with anti-VEGF drugs.
MATERIALS AND METHODS
A retrospective, non-randomised, multicentre, con-
secutive, interventional case series study was per-
formed on 92 eyes from 92 highly myopic patients
(spherical equivalent (SE) >−6.0 dioptres and/or
axial length >26.0 mm) from ﬁve different centres
in Spain and Portugal with more than 4 years
follow-up. Patients with retinal drusen in the study
or fellow eye or any evidence of age-related
macular degeneration were excluded. All patients
had presented with active subfoveal classic CNV
and had been treated by intravitreal injections (IVI)
of anti-VEGF drugs. The treating drug (IVR 0.5 mg
or IVB 1.25 mg) and initial protocol (loading dose
3 vs 1 injection) were dictated by surgeon’s prefer-
ence. After the initial dose an as-needed (PRN)
monthly regimen was used.
The study was performed in accordance with the
ethical standards of the 1964 Declaration of
Helsinki, and data gathering was performed after
obtaining written informed consent from each
patient and approval from the local ethics
committees.
A complete ocular examination including deter-
mination of best corrected visual acuity (BCVA)
and macular examination by spectral domain
optical coherence tomography (SD-OCT) was per-
formed at the ﬁrst visit and then monthly during
follow-up. BCVA was determined at 4 m using
standard Early Treatment Diabetic Retinopathy
Study (ETDRS) charts (Lighthouse, New York,
USA) by certiﬁed optometrists. Fluorescein angiog-
raphy (FA) was performed at baseline and when-
ever CNV activity was suspected. All patients
completed the 4-year follow-up, attending at all
visits. Patients previously treated by PDT were
started on anti-VEGF therapy if they showed signs
of CNV activity (decreased visual acuity associated
with intraretinal or subretinal ﬂuid and ﬂuorescein
leakage).
Patients were informed about the off-label condi-
tion of this therapy and women of childbearing age
were also informed about the possible risks to the
fetus; these patients agreed to use two forms of
contraception (barrier and hormonal) throughout
the following 3 months after injection. At each visit
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the patients were speciﬁcally asked about the appearance of sys-
temic side effects (medication changes, high blood pressure,
signs of cerebrovascular accidents, myocardial infarction or
ischaemia) and ocular side effects (pain, ﬂoaters, reduced visual
acuity).
The primary aim of the study was to analyse the changes in
the number of letters read during the 4-year follow-up period
after anti-VEGF therapy for subfoveal myopic CNV. The role of
age (<50 vs ≥50 years of age), SE, anti-VEGF drug and previ-
ous PDT on the visual outcome were evaluated as secondary
objectives.
Anti-VEGF re-injections were performed following the same
criteria in all the centres during follow-up in those cases with
signs of CNV activity: visual acuity loss ≥1 ETDRS line asso-
ciated with increased central foveal thickness <30 microns and/
or macular haemorrhage and/or increased intraretinal or subret-
inal ﬂuid. FA was performed in order to conﬁrm the presence of
ﬂuorescein leakage in the macular area.
RESULTS
The mean age of the patients was 57 years (SD 14 years, range
30–93); 27 (29%) were men. The right eye was affected in 48
patients. The mean SE was −12.4 dioptres (SD 4.4, range −5.0 to
−25). Thirty-seven eyes (40%) had undergone previously unsuc-
cessful PDT to treat myopic CNV: seven times in one eye, six
times in ﬁve eyes, four times in three eyes, three times in four eyes,
twice in nine eyes and once in 14 eyes. The last PDT session had
been performed at least 3 months prior to the ﬁrst injection with
anti-VEGF in all cases. All these cases presented with ﬂuorescein
leakage when they were included. Twenty-four eyes were treated
with IVR and 68 eyes with IVB. Seventy-seven patients were
treated with one single IVB or IVR as initial protocol. The demo-
graphic characteristics of these patients are shown in table 1.
A 4-year follow-up was completed in all cases. The mean
number of ETDRS letters read was 46.1 (SD 16.8, range 5–70)
at baseline, 55.5 (SD 18.6, range 10–85) at 12 months, 50.1
(SD 20.1, range 5–82) at 24 months, 54.2 (SD 21.9, range 2–
85) at 36 months and 53.1 (SD 22.5, range 1–83) at 48 months
(p=0.000, initial vs 12, 24 and 36 months and p=0.01 initial
vs 48 months, Student t test for paired data).
The mean number of re-injections after the loading dose was
3.6 (SD 5.4, range 0–28) and the mean total number of injec-
tions was 4.9 (SD 5.4, range 1–29). Seventeen patients required
seven or more re-injections (six of them had been previously
treated by PDT) and 10 cases required 12 or more IVI (three of
them previously treated by PDT). No systemic adverse reactions
were detected during follow-up. Two cases with lens opacity
progression were detected during follow-up that were not attrib-
uted to the treatment.
Average BCVA gain in treatment-naïve eyes was +3.7±21.8
letters (p=0.21) versus +7.1±15.0 letters in previously
PDT-treated eyes (p=0.007, both Student t test for paired data).
Previous PDT did not seem to inﬂuence BCVA changes after
anti-VEGF treatment (p=0.4, Student t test for unpaired data)
or the number of IVI required (5.3±5.9 vs 4.4±4.5, respect-
ively; p=0.5, Student t test for unpaired data). However, PDT
treatment-naïve eyes showed better initial and ﬁnal visual acuity
than previously PDT-treated eyes, even though BCVA gain was
lower in the former group (ﬁgure 1).
Considering BCVA changes in the treatment-naïve or
PDT-treated eyes that underwent IVB or IVR injections, the dif-
ferences were not statistically signiﬁcant: 4.5 vs 1.5 letters
gained for the treatment-naïve eyes treated by IVB and IVR,
respectively; 6.8 vs 7.6 letters gained for the previously
PDT-treated eyes injected with IVB and IVR, respectively
(p=0.56, ANOVA test).
The type of drug injected did not affect the visual outcome
(+5.3±19.3 letters with IVB and +4.3±14.8 letters with IVR;
p=0.85, ANOVA test). The inﬂuence of the anti-VEGF drug
used (bevacizumab, ranibizumab) on the number of re-injections
performed was not signiﬁcant (post hoc Bonferroni test).
The initial loading dose had no effect on the number of
re-injections required (3.9±5.7 injections vs 2.1±3.6 in eyes
treated with one or three previous injections, respectively;
p=0.2, Student t test).
The correlation between BCVA change and age was low but
signiﬁcant (r=−0.19; p=0.04; Pearson correlation test) but non-
signiﬁcant for SE (r=0.12; p=0.22; Pearson correlation test).
Multiple regression analysis for the main variables (age, SE,
initial BCVA, letters gained, SD-OCT ﬁndings, previous PDT,
anti-VEGF drug, initial protocol, number of re-injections, total
injections) showed similar results, with signiﬁcant correlation
for visual acuity gain and age (R2=0.220; p<0.001). SE and
treating drug had no inﬂuence on ﬁnal visual acuity and the
number of injections required, and the number of injections was
not related to visual gain.
Table 1 Demographic characteristics of patients treated with one single injection of bevacizumab and ranibizumab as initial protocol
Bevacizumab (n=53) Ranibizumab (n=24) p Value
Age (years) 57±14 (31–93) 54±15 (35–75) 0.48*
Sex (M/F) 14/39 6/18 0.85†
Eye (R/L) 26/27 15/9 0.58†
Spherical equivalent (D) −12.5±4.1 (−6 to −25) −12.4±4.5 (−5 to −21) 0.91*
% photodynamic therapy 17 (32%) 13 (54%) 0.86†
BCVA initial 44.3±19.2 (5–70) 50.1±12.6 (20–68) 0.18*
BCVA final 49.8±24.2 (5–82) 54.5±17.9 (15–83) 0.40*
Change in number of letters read 5.4±20 (−53 to 67) 4.3±14.8 (−23 to 36) 0.81*
Number of retreatments 4.7±6.4 (0–15) 2.3±3.0 (0–10) 0.10*
Total intravitreal injection 5.7±6.4 (1–16) 3.3±3.0 (1–11) 0.10*
Data shown are mean±SD (range).
*Mann–Whitney U test.
†χ2 test.
BCVA, best-corrected visual acuity letters read; D, dioptres; L, Left eye; R, Right eye.
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DISCUSSION
The good results obtained by intravitreal anti-VEGF therapy in
CNV secondary to age-related macular degeneration9 and the
increased VEGF expression in myopic CNV15 have set the
rationale for anti-VEGF therapy in myopic CNV.
Our results and those of several series in the literature show
that intravitreal anti-VEGF drugs are effective in treating myopic
CNV. However, Sawada et al16 and Shin et al17 have recently
reported that the VEGF concentration in the aqueous humour
of patients with myopic CNV is lower than in normal controls.
These authors have hypothesised that decreased aqueous VEGF
levels may be secondary to a disruption of the VEGF/pigment
epithelial derived factor balance in retinal pigment epithelium
(RPE) cells in highly myopic eyes. Nevertheless, high levels of
VEGF might be localised in or around the CNV, explaining the
anti-angiogenic beneﬁt of anti-VEGF therapy.
Bevacizumab has been the most widely used drug, and several
short series have reported good visual and anatomical out-
comes.4 6 18 These results are maintained after 1 year of
follow-up.5 19 20 Gharbiya et al,20 Chan et al19 and
Ruiz-Moreno et al5 reported very similar visual outcomes and
signiﬁcant visual improvement at 1-year follow-up using a three
consecutive IVB loading phase with no treatment-related sys-
temic or ocular complications. Peiretti et al12 have reported on
the persistent effectivity of IVB even after 4 years of follow-up.
However, the initial use of three IVB injections as a therapeutic
protocol is controversial due to the usually low activity of
myopic CNV.21 Further studies at 1-year follow-up used one
single initial dose of IVB. Ikuno et al3 treated 63 eyes with 1 mg
IVB; LogMAR BCVA improved from 0.57 to 0.33 at
12 months. Ruiz-Moreno et al22 reported a signiﬁcant improve-
ment in the number of ETDRS letters read (mean 8.7 letters)
during a 12-month follow-up; visual improvement occurred
during the ﬁrst 3 months and remained stable.
Similarly good results have been reported after one single
injection of ranibizumab followed by PRN treatment. Silva
et al2 reported an average visual acuity gain of eight letters from
baseline to 12 months after an average of 3.6 injections and no
systemic or ocular side effects,and Hefner et al23 have reported
good results after 1 year of follow-up.
In our series, some patients presented with persistent CNV
and required a higher number of re-injections. Those patients
who required a higher number of IVI showed a poorer ﬁnal
visual gain. We have not observed any singular pattern among
such patients in terms of age or SE.
Series of eyes treated with one versus three consecutive injec-
tions have been compared showing that one single initial injec-
tion followed by PRN therapy is usually enough,13 probably
because of the low activity of myopic CNV.19 We have not
found differences in our series after 4 years of follow-up; the
initial loading dose had no effect on the number of re-injections
required.
All these series show the same limitation—namely, the lack of
a PDT-treated control group as the ﬁrst-line therapy approved
for myopic CNV following the results of the VIP 1 trial.1 Series
comparing PDT versus IVB to treat myopic CNV agree in a
higher visual acuity gain with anti-VEGF after 1 and 2 years of
follow-up.14 24–27 Yoon et al27 retrospectively compared the
results of 51 eyes with myopic CNV treated by PDT, 63 eyes
treated with intravitreal anti-VEGF drugs and 28 eyes treated
with a combined therapy PDT plus anti-VEGF at 1-year
follow-up. The authors concluded that intravitreal anti-VEGF
was more effective than PDTalone or combined therapy to treat
myopic CNV. Ikuno et al25 analysed the results after treating 31
eyes with myopic CNV in Japanese women who received either
PDT or IVB. Baba et al14 compared 12 eyes treated with PDT
with 12 eyes treated by IVB. Both groups concluded that IVB
was superior to PDT in myopic CNV. Hayashi et al performed a
prospective non-randomised study comparing the results of 44
eyes with myopic CNV treated by PDT and 43 eyes treated by
IVB. IVB was more effective and BCVA improved from 0.68 to
0.45 (LogMAR) in the bevacizumab group versus 0.61 to 0.54
in the PDT group.24 Ruiz-Moreno et al performed a prospective
randomised multicentre study comparing the results of 28 eyes
with myopic CNV treated by PDT and 27 eyes treated by IVB.
Bevacizumab was more effective at 1 year and BCVA changed
from 53.0 to 64.2 ETDRS letters in the bevacizumab group
versus 52.8 to 52.5 in the PDT group.26
Reported series with 2 years follow-up show a decline in
BCVA28 that has been attributed to atrophic changes associated
with high myopia.24 However, the extent of this 2-year decline
is controversial. Hayashi7 (75 eyes) and Ruiz-Moreno and
Montero29 (19 eyes) did not ﬁnd a statistically signiﬁcant
decline in BCVA between baseline and 2 years, and Chen30 (26
eyes) reported a signiﬁcant gain in BCVA by the end of the
second year.
To the best of our knowledge, only one retrospective non-
randomised study with 4 years of follow-up has been published
on 21 eyes with myopic CNV treated with bevacizumab.12 In
this series, 15/21 eyes gained one or more lines, three eyes
remained stable within one line and three eyes lost one or more
lines.
OCT ﬁndings were signiﬁcantly related to ﬁnal BCVA. Best
results were observed for eyes without signiﬁcant OCT changes
after treatment and the poorer results occurred in eyes with
atrophic changes, probably associated with damage to the RPE
and the outer segment of the photoreceptors.31 The response to
IVI was poorer in eyes with subfoveal lesions in terms of
re-injections and VA gain, as has been previously reported.7
It has been reported that previous PDT may lead to a poorer
visual outcome in eyes treated with anti-VEGF drugs,32 whereas
other series have shown that previous PDT had no inﬂuence on
the ﬁnal visual acuity.22 PDT might inﬂuence visual acuity out-
comes by varied mechanisms including choroidal ischaemia or
damage to the RPE and photoreceptors. According to our ﬁnd-
ings, previous PDT did not affect the ﬁnal visual outcome or
the number of IVI.
Our results conﬁrm the statistically signiﬁcant visual acuity
gain in myopic eyes treated with anti-VEGF drugs. The type of
Figure 1 Best-corrected visual acuity changes in treatment-naïve and
previous photodynamic therapy (PDT)-treated eyes.
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anti-VEGF drug used and previous PDT did not induce any dif-
ference. Correlation with SE was not statistically signiﬁcant and
a low but signiﬁcant correlation was found between BCVA
change and age. BCVA gain was more marked in younger
patients. The comparative efﬁcacy of bevacizumab and ranibizu-
mab was similar. No systemic adverse reactions were detected
during follow-up.
Among the limitations of the current study we should high-
light that this is a non-randomised retrospective study and that
more eyes were treated with bevacizumab than with ranibizu-
mab (68 and 24 eyes, respectively). We also lack a control group
with PDT; however, following the recent reports comparing
PDTand anti-VEGF drugs, the latter are markedly superior. The
strengths of the study are the high number of treated eyes (92
eyes) with long follow-up (4 years), based on real practice in dif-
ferent centres.
According to our results, anti-VEGF drugs are useful for the
treatment of CNV associated with high myopia, achieving sig-
niﬁcant BCVA gain at long follow-up, and must be considered
as ﬁrst-line therapy. Bevacizumab and ranibizumab had similar
clinical effects in BCVA gain and number of IVI required.
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